Y Intercept Hong Kong Ltd Buys New Shares in Bausch Health Cos Inc. $BHC

Y Intercept Hong Kong Ltd bought a new position in Bausch Health Cos Inc. (NYSE:BHC) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 24,761 shares of the company’s stock, valued at approximately $165,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Alpha Wealth Funds LLC acquired a new position in shares of Bausch Health Cos in the second quarter valued at about $65,000. Stratos Wealth Advisors LLC acquired a new stake in shares of Bausch Health Cos during the second quarter worth about $67,000. TD Asset Management Inc lifted its holdings in shares of Bausch Health Cos by 5.0% during the second quarter. TD Asset Management Inc now owns 889,912 shares of the company’s stock worth $5,922,000 after purchasing an additional 42,236 shares during the period. Atria Wealth Solutions Inc. boosted its position in Bausch Health Cos by 20.7% in the second quarter. Atria Wealth Solutions Inc. now owns 37,014 shares of the company’s stock valued at $261,000 after buying an additional 6,348 shares during the last quarter. Finally, Viewpoint Capital Management LLC increased its holdings in Bausch Health Cos by 20.4% in the 2nd quarter. Viewpoint Capital Management LLC now owns 28,900 shares of the company’s stock worth $192,000 after buying an additional 4,900 shares during the period. Institutional investors and hedge funds own 78.65% of the company’s stock.

Insiders Place Their Bets

In other news, Director John Paulson acquired 34,721,118 shares of the business’s stock in a transaction on Thursday, August 14th. The stock was bought at an average price of $9.00 per share, with a total value of $312,490,062.00. Following the completion of the acquisition, the director owned 70,755,869 shares of the company’s stock, valued at approximately $636,802,821. This represents a 96.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have acquired a total of 35,964,167 shares of company stock valued at $321,057,793 over the last three months. 19.97% of the stock is currently owned by insiders.

Bausch Health Cos Stock Performance

BHC opened at $6.64 on Monday. The company has a debt-to-equity ratio of 141.90, a current ratio of 1.31 and a quick ratio of 0.98. The firm has a fifty day moving average price of $6.65 and a 200 day moving average price of $6.19. Bausch Health Cos Inc. has a 1 year low of $4.25 and a 1 year high of $9.49. The stock has a market cap of $2.46 billion, a P/E ratio of 25.52 and a beta of 0.47.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BHC. Weiss Ratings reissued a “hold (c)” rating on shares of Bausch Health Cos in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Three research analysts have rated the stock with a Hold rating, According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $9.00.

Bausch Health Cos Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.